New study aims to stop bleeding in kidney stone surgery

NCT ID NCT07668817

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether using a hemostatic agent (a substance that stops bleeding) during kidney stone surgery can reduce blood loss compared to standard care. About 92 adults with kidney stones will be randomly assigned to receive either a hemostatic agent or no agent during their procedure. The main goal is to see if hemoglobin levels (a measure of red blood cells) drop less after surgery with the agent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hemostatic agents (Floseal, Surgicel, Surgiflo) or balloon tamponade
What this could lead to: If successful, this could show that using a hemostatic agent during kidney stone surgery reduces blood loss, potentially improving recovery.
What could go wrong: This is a small, early-stage trial with only 92 participants. The results may not apply to all patients, and the agents could have side effects like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROLITHIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEPHROLITHIASIS

Contacts and locations

Locations

Mount Sinai West
RECRUITING

New York, New York, 10019, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.